Myriad Genetics, Inc.MYGNrecently entered into a research partnership with National Cancer Center Hospital East ("NCCHE") in Japan to evaluate the prognostic and predictive value of molecular residual disease (MRD) testing. Myriad Genetics' Precise MRD test will be used to investigate the widespread...
today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National Comprehensive Cancer Network®(NCCN®) Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma (DLBCL), following the company
announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in ...
DeciBio conducted 10 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care Publish Date December 12, 2023 Category Ad Board Reports Price $ 2,750.00 USD ...
, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to s...
Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.
It synthesizes currently available evidence, reviews region-specific clinical trends, addresses critical clinical questions related to MRD testing, and offers recommendations to guide healthcare professionals, biotechnology and pharmaceutical companies, and regulatory authorities. These recommendations were ...
(CLIA) inAustin, TexasandSan Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software...
We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of deidentified clinical lab results, Quest's diagnostic insights reveal new avenues ...
Adaptive is committed to efforts that will expand access to clonoSEQ testing for patients across the U.S. Building on its flagship integration partnership with Epic, Adaptive will continue to pursue integration opportunities with other oncology EMR vendors...